Celcuity Inc. (NASDAQ:CELC) Short Interest Up 9.3% in October

Celcuity Inc. (NASDAQ:CELC - Get Free Report) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 3,530,000 shares, a growth of 9.3% from the September 30th total of 3,230,000 shares. Based on an average daily volume of 306,800 shares, the days-to-cover ratio is currently 11.5 days.

Institutional Investors Weigh In On Celcuity

Several institutional investors have recently made changes to their positions in CELC. nVerses Capital LLC acquired a new position in Celcuity in the third quarter valued at $33,000. Values First Advisors Inc. acquired a new stake in shares of Celcuity during the 3rd quarter valued at approximately $86,000. Quest Partners LLC boosted its holdings in shares of Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock valued at $95,000 after buying an additional 1,379 shares during the period. SG Americas Securities LLC bought a new position in Celcuity during the 3rd quarter worth $119,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Celcuity by 78.5% in the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company's stock worth $193,000 after acquiring an additional 3,930 shares during the period. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Trading Down 0.3 %

Shares of Celcuity stock traded down $0.05 during trading hours on Wednesday, hitting $15.86. The company's stock had a trading volume of 84,711 shares, compared to its average volume of 276,647. The firm has a fifty day moving average of $15.46 and a 200-day moving average of $16.18. The stock has a market cap of $556.70 million, a price-to-earnings ratio of -5.71 and a beta of 0.75. Celcuity has a twelve month low of $9.91 and a twelve month high of $22.19. The company has a debt-to-equity ratio of 0.54, a quick ratio of 14.95 and a current ratio of 14.95.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.09. During the same period in the previous year, the company earned ($0.66) EPS. Research analysts forecast that Celcuity will post -2.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Stifel Nicolaus lifted their price objective on Celcuity from $39.00 to $42.00 and gave the company a "buy" rating in a research note on Monday, October 7th. Needham & Company LLC reiterated a "buy" rating and issued a $23.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Lifesci Capital began coverage on shares of Celcuity in a report on Monday, August 26th. They issued an "outperform" rating and a $27.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $27.00 price objective on shares of Celcuity in a research report on Thursday, August 15th. Finally, Leerink Partnrs raised Celcuity to a "strong-buy" rating in a research report on Monday, July 22nd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Celcuity currently has a consensus rating of "Buy" and an average target price of $29.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.